Evidence Hub

Korvitin reduces the high maintenance of myeloperoxidase in plasma of blood of patients with the acute infarct of myocardium.

Ryzhkova NO, Gavrilenko TI, Parkhomenko OM

Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 2016

60 participants

Abstract

We studied the content of myeloperoxidase in plasma of blood, which is a new additional marker of the metabolic activity of phagocytes and the activity of inflammation in patientes with the acute infarct of myocardium and possibility of its correction of Korvitin. We inspected 15 practically healthy persons in which the content of myeloperoxidase was 74,5±16,3 ng/ml, 13 patients with a stable stenocardia (the conent of myeloperoxidase was 218,4±30,9 ng/ml) and 60 patients with acute infarct of myocardium (the content of myeloperoxidase was 606,0±59,3 ng/ml at the beginning of therapy) in the dynamics of treatment. In patients accepting standard treatment (without application of Korvitin), the content of myeloperoxidase was unchanged during 7 days of treatment. It patients administered korvitin, the action of this preparation depended on the initial level of myeloperoxidase. In Patients with the initial normal plasma content of myeloperoxidase (16,7%), its content insignificantly increased during the time course of the treatment, while in patients with the high initial level of myeloperoxidase (83,3%), its level declined during treatment.

How strong is the evidence?

Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 60 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free